Last reviewed · How we verify

NCT04549506

Autism, Emotional Processing, and the Amygdala

Completed Last updated 16 September 2020
What this trial tests

trial in Autism Spectrum Disorder in 51 participants. Completed in 16 June 2017.

Timeline
19 April 2014
Primary endpoint
21 September 2016
16 June 2017

Quick facts

Lead sponsorYawei Cheng
StatusCompleted
Study typeOBSERVATIONAL
Enrollment51
Start date19 April 2014
Primary completion21 September 2016
Estimated completion16 June 2017

Conditions studied

Sponsor

Yawei Cheng

Who can join

Adults 13 to 40, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Empathy imbalance hypothesis suggests that individuals with autism Spectrum Disorder (ASD) should have a deficit of cognitive empathy and a surfeit of emotional empathy. Considering that inconsistent amygdala reactivity to emotional faces might be ascribed to aberrant attention in ASD, the investigators hypothesized to investigate if there would be an imbalance between conscious and nonconscious emotional processing. This fMRI study recruited 26 youths and young adults with autism spectrum disorder and 25 matched controls, and measured their amygdala reactivity and functional connectivity in response to conscious and nonconscious (backward masked) perception of threatening faces. Keywords: Autism Spectrum Disorder; amygdala reactivity; emotional processing; fMRI

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04549506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing